3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
4
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Stress Disorders, Post-Traumatic
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pain
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Locally Advanced Colorectal Cancer
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Hemorrhage
1
Bites and Stings
1
Interventions
Docetaxel
137
Prednisone
120
Abiraterone Acetate
91
Leuprolide
86
enzalutamide
84
Radiotherapy
59
bicalutamide
56
Magnetic Resonance Spectroscopy
54
Goserelin
54
Androgen Antagonists
51
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
47
apalutamide
44
abiraterone
34
Radiosurgery
31
Specimen Handling
30
gallium 68 PSMA-11
29
Gonadotropin-Releasing Hormone
29
cabazitaxel
28
Carboplatin
27
darolutamide
25
Estramustine
24
luprolide acetate gel depot
23
relugolix
22
Metformin
22
Triptorelin Pamoate
20
sipuleucel-T
19
radium Ra 223 dichloride
19
Radiation
19
pembrolizumab
18
deltacortene
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Prostatic Neoplasms
×
Palliative Care
×
Clear all
NCT03652298
2026-03-13
NeuroPrevPTSD
Centre Oscar Lambret
Phase 2
Terminated
19 enrolled